General Information
Drug ID
DR00037
Drug Name
Cimetidine
Synonyms
1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine; 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine; 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; Acibilin; Acinil; Altramet; Biomet400; Brumetidina; C 4522; CIMETIDINE A/AB; Ci metum; Cimal; Cimetadine; Cimetag; Cimetidina; Cimetidina [INN-Spanish]; Cimetidine (JP15/USP/INN); Cimetidine Hcl; Cimetidine [USAN:INN:BAN:JAN]; Cimetidinum; Cimetidinum [INN-Latin]; Cimetum; DRG-0150; Dyspamet; Edalene; Eureceptor; Evicer; FPF 1002; Gastrobitan; Gastromet; Histodil; Magicul; Metracin; N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine; N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1 H-imidazol-4-yl) methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; N-cyano-N'-methyl-N''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; Peptol; SK&F-92334; SKF 92334; SKF-92334; Sigmetadine; Tagamet; Tagamet (TN); Tagamet HB (TN); Tagamet HB200 (TN); Tagamet Hb; Tagamet Hb 200; Tagamet, SKF-92334, Tratul, Tametin, Dyspamet, Acinil, Cimetidine; Tametin; Tratul; Ulcedin; Ulcedine; Ulcestop; Ulcimet; Ulcofalk; Ulcomedina; Ulcomet; Ulhys; Valmagen; Venopex
Drug Type
Small molecular drug
Indication Acid reflux disorder [ICD11: DA22] Approved [1]
Therapeutic Class
Antiulcer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=2756"></iframe>
3D MOL 2D MOL
Formula
C10H16N6S
Canonical SMILES
CC1=C(N=CN1)CSCCNC(=NC)NC#N
InChI
InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)
InChIKey
AQIXAKUUQRKLND-UHFFFAOYSA-N
CAS Number
CAS 51481-61-9
Pharmaceutical Properties Molecular Weight 252.34 Topological Polar Surface Area 114
Heavy Atom Count 17 Rotatable Bond Count 7
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 4
XLogP
0.4
PubChem CID
2756
PubChem SID
10321166 , 10524846 , 11110948 , 11113773 , 11335341 , 11360580 , 11363389 , 11365951 , 11368513 , 11372297 , 11374462 , 11376675 , 11407328 , 11461552 , 11484620 , 11488598 , 11491204 , 11492627 , 11494309 , 11533056 , 12013445 , 14774387 , 15122273 , 15196790 , 17389962 , 17404856 , 22391437 , 24277766 , 24531048 , 26612025 , 26679798 , 26747359 , 26747360 , 26751956 , 26751957 , 29221911 , 4266417 , 4493559 , 460110 , 46487919 , 46505360 , 47275096 , 615111 , 6699439 , 6897918 , 7847361 , 7978946 , 8147032 , 8149633 , 9167
ChEBI ID
ChEBI:3699
TTD Drug ID
D02DPA
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MATE1 Transporter Info Multidrug and toxin extrusion protein 1 Substrate [3]
MATE2 Transporter Info Multidrug and toxin extrusion protein 2 Substrate [3]
OAT3 Transporter Info Organic anion transporter 3 Substrate [4]
OCT1 Transporter Info Organic cation transporter 1 Substrate [5]
OCT2 Transporter Info Organic cation transporter 2 Substrate [6]
P-GP Transporter Info P-glycoprotein 1 Substrate [7]
Drug-Transporter Activity Data
Drug-Transporter Activity Data MATE1 Transporter Info Km = 170 microM Human embryonic kidney cells (HEK293)-MATE1 [3]
MATE2 Transporter Info Km = 120 microM Human embryonic kidney cells (HEK293)-MATE2K [3]
MATE2 Transporter Info Km = 370 microM Human embryonic kidney cells (HEK293)-MATE2K [8]
OAT3 Transporter Info Km = 174 microM Chinese hamster ovary (CHO) cells-OAT3 [4]
OAT3 Transporter Info Km = 113 microM Human embryonic kidney cells (HEK293)-OAT3 [9]
OAT3 Transporter Info Km = 149 microM Human embryonic kidney cells (HEK293)-OAT3 [10]
OAT3 Transporter Info Km = 57.4 microM Oocytes-OAT3 [11]
OCT2 Transporter Info Km = 60 microM Human embryonic kidney cells (HEK293)-OCT2 [5]
OCT2 Transporter Info Km = 72.6 microM Human embryonic kidney cells (HEK293)-OCT2 [12]
References
1 Cimetidine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol. 2008 Mar;73(3):613-5.
3 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
4 Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007 May;321(2):673-83.
5 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
6 Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34.
7 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
8 Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006 Aug;17(8):2127-35.
9 Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos. 2006 May;34(5):743-7.
10 Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94.
11 Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
12 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.